A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects

In 2019, they launched Delix Therapeutics, tapping Shire neuroscience vet Mark Rus to guide the Boston-based biotech into the clinic. And on Monday, they unveiled a $70 million Series A round led by ARTIS Ventures, RA Capital Management and OMX.